相关实验视频

Updated: Jun 9, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

对抗PD-1/PD-L1免疫疗法的新增剂:抑制PCSK9

Shengbo Sun¹, Zhengyang Yang², Hongwei Yao²

¹Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing, China; Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Trends in cancer

|October 25, 2024

概括

抑制蛋白转化酶亚提利辛/凯类型9 (PCSK9) 可以提高抗编程细胞死亡蛋白1 (PD-1) /PD-1连接体1 (PD-L1) 癌症免疫疗法的有效性. 这种方法解决了许多患者的低响应率,为癌症治疗提供了新的策略.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

反编程细胞死亡蛋白1 (PD-1) /PD-1连接体1 (PD-L1) 免疫疗法可以改善癌症治疗结果.
大多数患者对PD-1/PD-L1阻塞的反应有限,需要新的治疗增强剂.

研究的目的:

调查抑制蛋白转化酶亚提利辛/凯类型9 (PCSK9) 的潜力,作为增强抗PD-1/PD-L1免疫治疗疗效的策略.

主要方法:

这项研究的重点是PCSK9抑制影响瘤微环境和免疫反应的机制.

主要成果:

新出现的数据表明,抑制PCSK9,一种血清蛋白酶,可以增强PD-1/PD-L1阻塞的抗瘤作用.
这表明PCSK9抑制和检查点阻塞免疫疗法之间存在协同作用的关系.

结论:

抑制PCSK9是一种有希望的策略,可以克服耐药性并改善患者对PD-1/PD-L1免疫疗法的反应.
进一步研究PCSK9作为癌症免疫治疗的增强剂是有必要的.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...